A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer
A Phase II Trial of AK104 in Combination With Docetaxel in Subjects With Advanced Non-Small Cell Lung Cancer and Progressive Disease After Platinum Doublet Chemotherapy and Treatment With One Prior Anti-PD-1/PD-L1 Monoclonal Antibody (mAb)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Jifeng Feng, MD
- Phone Number: 025-83284707
- Email: fjif@vip.sina.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210009
- Jiangsu Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 to 75 years old.
- Have a life expectancy of at least 3 months.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Has a histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC.
- Has radiographic progression after prior platinum doublet chemotherapy and anti-PD-1/PD-L1 monoclonal antibody (mAb) administered.
- No known epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations.
- Has at least 1 measurable lesion per RECIST 1.1 assessed by investigator.
- Has adequate organ function.
Exclusion Criteria:
- Undergone major surgery within 30 days prior to the first dose of study treatment.
- Active central nervous system (CNS) metastases.
- History of active autoimmune disease that has required systemic treatment in the past 2 years (i.e.,corticosteroids or immunosuppressive drugs).
- Active Hepatitis B or Hepatitis C.
- Received previous immunotherapy, including immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy and other treatments targeting the mechanism of tumor immunity.
- Has received treatment with docetaxel.
- History of severe bleeding tendency or coagulation disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AK104 plus Docetaxel
AK104 RP2D + Docetaxel 75mg/m^2 every 3 weeks until progressive disease or unacceptable toxicity.
|
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Objective Response Rate (ORR)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival (OS)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Number of patients with Adverse Events (AEs)
Time Frame: Up to approximately 2 years
|
Characterization of incidence, severity and abnormal clinically significant laboratory findings of AEs
|
Up to approximately 2 years
|
|
Disease control rate (DCR)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Duration of Response (DOR)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Time to response (TTR)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Progression free survival (PFS)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Pharmacokinetic Parameter Area Under the Plasma Concentration-Time Curve (AUC) Of AK104
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
Antidrug antibodies (ADA) of AK104
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Organic Chemicals
- Hydrocarbons
- Cycloparaffins
- Hydrocarbons, Alicyclic
- Hydrocarbons, Cyclic
- Terpenes
- Taxoids
- Cyclodecanes
- Diterpenes
- Docetaxel
Other Study ID Numbers
Other Study ID Numbers
- AK104-215
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.